Seres Therapeutics Stock Prediction and Forecast [MCRB]

AI-generated source summary

Seres Therapeutics (MCRB) stock shows a mix of signals. While short-term moving averages indicate a positive outlook, a general sell signal is present due to the long-term average being above the short-term average. On pullbacks, support is expected at $16.29 and $17.75. A break below these levels could trigger sell signals. A buy signal was issued from a pivot bottom on November 5, 2025, leading to a 70.39% rise. Further increases are anticipated until a new pivot top is established. Additionally, a buy signal from the 3-month Moving Average Convergence Divergence (MACD) suggests rising volume and price, which is a positive technical indicator. However, recent price action and analyst ratings suggest caution. The stock has experienced significant daily volatility, increasing risk. With a P/E ratio of 27.22, it's considered overvalued compared to industry averages. Recent insider trading shows multiple buy transactions, indicating positive sentiment from company insiders. Analysts have provided mixed ratings, with some BUY ratings and others SELL or NEUTRAL, highlighting the uncertainty. We expect MCRB to open lower on November 18th, trading down $1.39 at $20.25, and a potential break of the $19.39 support level could lead to further declines. Therefore, we maintain a HOLD recommendation.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   18 Nov 2025, 04:00 UTC

   The analyst published the original source item.

2. First prediction resolved

   18 Nov 2025, 14:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   18 Nov 2025, 14:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:12 UTC

   Tahlil Plus began monitoring the extracted predictions.